Catalog No.
YXX00402
Expression system
Bacillus Subtilis
Species
Bacillus anthracis
Protein length
Glu30-Gly764
Predicted molecular weight
87.45 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P13423
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Protective antigen, PA, Anthrax toxins translocating protein, PA-83, PA83, Protective antigen PA-20, PA-20, PA20, Protective antigen PA-63, PA-63, PA63, pagA, pag, pXO1-110, BXA0164, GBAA_pXO1_0164
A Nasal Vaccine Displaying Anthrax Antigen on the Surface of Lactiplantibacillus plantarum Induces Protective Mucosal Immunity against Anthrax Toxin., PMID:40443240
FapR regulates HssRS-mediated heme homeostasis in Bacillus anthracis., PMID:40407322
ATP depletion in anthrax edema toxin pathogenesis., PMID:40168442
ERK pathway reactivation prevents anthrax toxin lethality in mice., PMID:40155776
Identification of Potential Therapeutic Targets Against Anthrax-Toxin-Induced Liver and Heart Damage., PMID:39998071
Electrochemical immunosensor for Bacillus anthracis PA toxin using a polypyrrole-gold nanoparticle/multiwall carbon nanotube sensing platform and cadmium sulphide nanocrystal signal tag., PMID:39851166
MAP Kinase Signaling at the Crossroads of Inflammasome Activation., PMID:39754394
Toxin and capsule production by Bacillus cereus biovar anthracis influence pathogenicity in macrophages and animal models., PMID:39715264
Repurposing FDA-approved disulfiram for targeted inhibition of diphtheria toxin and the binary protein toxins of Clostridium botulinum and Bacillus anthracis., PMID:39346565
Targeting canine mammary neoplastic epithelial cells with a reengineered anthrax toxin: first study., PMID:38805149
Split fluorescent protein-mediated multimerization of cell wall binding domain for highly sensitive and selective bacterial detection., PMID:38750815
Genetic basis of clarithromycin resistance in Bacillus anthracis., PMID:38666793
Quantifying in vitro B. anthracis growth and PA production and decay: a mathematical modelling approach., PMID:38553532
Peptidoglycan from Bacillus anthracis Inhibits Human Macrophage Efferocytosis in Part by Reducing Cell Surface Expression of MERTK and TIM-3., PMID:38517345
Anthrax Toxin: Model System for Studying Protein Translocation., PMID:38458604
Central Nervous System Antimicrobial Exposure and Proposed Dosing for Anthrax Meningitis., PMID:38412060
Early Circulating Edema Factor in Inhalational Anthrax Infection: Does It Matter?, PMID:38399712
Visualization of immune pathways that enhance the neutralizing antibody response to vaccines after primary immunization., PMID:38334423
Efficacy of different AV7909 dose regimens in a nonclinical model of pulmonary anthrax., PMID:38115181
Anthrax lethal toxin and tumor necrosis factor-α synergize on intestinal epithelia to induce mouse death., PMID:37855658
Development of a New Cell-Based AP-1 Gene Reporter Potency Assay for Anti-Anthrax Toxin Therapeutics., PMID:37755954
Protective antigen of Bacillus anthracis in combination with TLR4 or TLR5 agonist confers superior protection against lethal challenge in mouse model., PMID:37437686
DARPins bind their cytosolic targets after having been translocated through the protective antigen pore of anthrax toxin., PMID:37198284
Immunogenicity and Protective Efficacy of Recombinant Protective Antigen Anthrax Vaccine (GC1109) in A/J Mice Model., PMID:37055344
Inhalable vaccine of bacterial culture supernatant extract mediates protection against fatal pulmonary anthrax., PMID:36920800
Alternate atxA and acpA dependent response of Bacillus anthracis to serum, HCO3- and CO2., PMID:36795682
Recombinant full-length Bacillus Anthracis protective antigen and its 63 kDa form elicits protective response in formulation with addavax., PMID:36713362
Modeling gastrointestinal anthrax disease., PMID:36646261
Comprehensive characterization of toxins during progression of inhalation anthrax in a non-human primate model., PMID:36534695
Welder's Anthrax: A Tale of 2 Cases., PMID:36251561
Clinical Features of Patients Hospitalized for All Routes of Anthrax, 1880-2018: A Systematic Review., PMID:36251560
Antitoxin Use in the Prevention and Treatment of Anthrax Disease: A Systematic Review., PMID:36251559
Pre- and Postlicensure Animal Efficacy Studies Comparing Anthrax Antitoxins., PMID:36251555
Systematic Review of Hospital Treatment Outcomes for Naturally Acquired and Bioterrorism-Related Anthrax, 1880-2018., PMID:36251553
New formulation of a recombinant anthrax vaccine stabilised with structurally modified plant viruses., PMID:36160184
Serological responses to Anthrax Vaccine Precipitated (AVP) increase with time interval between booster doses., PMID:36153153
Structural and Functional Analysis of Toxin and Small RNA Gene Promoter Regions in Bacillus anthracis., PMID:36043862
Role of serine/threonine protein phosphatase PrpN in the life cycle of Bacillus anthracis., PMID:35913993
Use of protective antigen of Bacillus anthracis as a model recombinant antigen to evaluate toll-like receptors 2, 3, 4, 7 and 9 agonists in mice using established functional antibody assays, antigen-specific antibody assays and cellular assays., PMID:35773119
Role of site-directed mutagenesis and adjuvants in the stability and potency of anthrax protective antigen., PMID:35693445
Designing Stable Bacillus anthracis Antigens with a View to Recombinant Anthrax Vaccine Development., PMID:35456639
An RNA-binding protein acts as a major post-transcriptional modulator in Bacillus anthracis., PMID:35314695
Structure of the Anthrax Protective Antigen D425A Dominant Negative Mutant Reveals a Stalled Intermediate State of Pore Maturation., PMID:35304125
Safety and immunogenicity of a plant-derived recombinant protective antigen (rPA)-based vaccine against Bacillus anthracis: A Phase 1 dose-escalation study in healthy adults., PMID:35153091
A multipathogen DNA vaccine elicits protective immune responses against two class A bioterrorism agents, anthrax and botulism., PMID:35141866
Identification of other Cellular Receptors for Edema Factor of Bacillus anthracis by Independent Inhibition of Protective Antigen Evidenced by Inhibition of Embryo Growth and Angiogenesis., PMID:35096320
Using a Syrian (Golden) Hamster Biological Model for the Evaluation of Recombinant Anthrax Vaccines., PMID:34947919
Anthrax toxins regulate pain signaling and can deliver molecular cargoes into ANTXR2+ DRG sensory neurons., PMID:34931070
Characterization of the adaptive immune response of donors receiving live anthrax vaccine., PMID:34928976
Imaging of anthrax intoxication in mice reveals shared and individual functions of surface receptors CMG-2 and TEM-8 in cellular toxin entry., PMID:34871548
For research use only. Not for human or drug use.
